Cybin Receives Expedited Review FDA Breakthrough | Trade To Black

In this episode of the Trade to Black Podcast, we sit down with Doug Drysdale, Chief Executive Officer of Cybin, to discuss the recent milestones and future prospects of their novel psychedelic molecule, CYB003.
#Cybin #Cybinstock #thedalesreport

Key topics covered in this interview:

FDA’s Breakthrough Therapy Designation
Phase 2 Trial Success
The Road to Phase 3
ICYB003’s fast onset of effects and its implications
Financial Strategy Insight

Get a glimpse into the key milestones and developments expected in Cybin’s pipeline, focusing on Psilocybin, DMT/d-DMT, and Phenethylamines.

Stay tuned to this episode to gain in-depth insights into Cybin's journey in revolutionizing the treatment of MDD with their innovative psychedelic therapies, following their recent announcement of FDA Breakthrough Therapy Designation for CYB003.

Have you subscribed to the Baked In Newsletter? 📜
Join 20k+ unfiltered investing elites. Get Baked In delivered to your inbox for free, 5 days a week
https://newsletter.thedalesreport.com...

Add us on:
Facebook:   / thedalesreport  
Twitter:   / thedalesreport  
Instagram:   / dalesreport  
Website: https://thedalesreport.com/

The information provided in this video is for educational purposes only and should not be considered as financial or investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions.

The Dales Report Inc. disclosure policy applies to this video:
https://thedalesreport.com/disclosure/

In accordance with an executed agreement between The Dales Report and the aforementioned entity, highlighted either directly or indirectly in the article, The Dales Report has been engaged for a stipulated contractual duration with the purpose of publicly disseminating information pertaining to the aforementioned entity via The Dales Report's media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for our services involves the receipt of a predefined monetary consideration, which may encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations.